In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based ...

In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and ...

Social determinants of health been long understood to influence health outcomes, and this new analysis explores more deeply the link between social risk exposure and rates of health care resource ...

The long-term impact of disruptions in oncology care during the COVID-19 pandemic will become more apparent in the coming years, according to Dan Nardi, MS, of Reimagine Care.

To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not ...

Experts discuss proactive steps health care teams, including pharmacists, can take to minimize delays and overcome payer-related barriers when prescribing third-line therapies for metastatic ...

Experts discuss effective strategies for navigating the prior authorization process to ensure timely access to third-line therapies for metastatic colorectal cancer (mCRC) and share any success ...

Strategies to enhance virtual care through quality assurance frameworks, technological innovation, and provider support were ...